By Fineline Cube Adagene Inc. (NASDAQ: ADAG) announced a new milestone achievement in its ongoing SAFEbody antibody‑drug conjugate (ADC) collaboration with Exelixis. Based on milestone progress achieved in the preclinical development of the collaboration molecule XB404, Exelixis made a USD 2 million milestone payment to Adagene. XB404 is built using Adagene’s SAFEbody technology and is designed to deliver cytotoxic payloads to ROR1/2‑expressing tumours while minimising toxic side effects targeting normal tissues.
Milestone Snapshot
| Item | Detail |
|---|---|
| Companies | Adagene Inc. (NASDAQ: ADAG); Exelixis |
| Agreement | SAFEbody ADC collaboration and license agreement |
| Milestone Event | Preclinical development progress of collaboration molecule XB404 |
| Payment | USD 2 million milestone payment from Exelixis to Adagene |
| Technology Licensed | Adagene SAFEbody precision‑activation platform |
| Announcement Date | 10 September 2026 |
| Remaining Milestones & Royalty Rates | Not disclosed |
Collaboration Structure & Economics
- Technology License: Under the collaboration and license agreement, Exelixis may use Adagene’s SAFEbody technology to develop monoclonal safe antibodies and further use them in the development of SAFEbody ADC candidate drugs.
- Revenue Entitlements: Adagene is eligible to receive development and commercialisation milestone payments, as well as royalties based on net product sales — a multi‑layer economics package spanning preclinical execution through commercialization.
- Current Trigger: The USD 2 million payment recognizes milestone progress in the preclinical development of XB404, the collaboration molecule built on SAFEbody technology.
XB404 Profile – SAFEbody ADC Targeting ROR1/2
- Molecule: XB404, a SAFEbody‑based ADC candidate developed under the collaboration.
- Target: ROR1/2 (receptor tyrosine kinase‑like orphan receptors 1 and 2), tumor‑associated antigens expressed across multiple hematologic and solid tumor types with restricted expression on normal adult tissues.
- Design Objective: Engineered to deliver cytotoxic payloads selectively to ROR1/2‑expressing tumours while minimising toxic side effects on normal tissues — addressing the on‑target/off‑tumor toxicity that has constrained conventional ADCs.
- Stage: Preclinical; trial timing and clinical design: Not disclosed.
Platform Technology – SAFEbody Precision Activation
- Concept: Adagene’s SAFEbody technology is a precision‑activation (masking) platform that keeps antibodies inert in circulation and unmasks their binding activity at the tumor site, aiming to widen the therapeutic window of both monoclonal antibodies and ADCs.
- ADC Application: Applied to conjugates, SAFEbody masking seeks to confine cytotoxic payload delivery to antigen‑expressing tumor tissue, reducing systemic exposure of healthy organs.
- Partner Validation: The Exelixis milestone payment represents external, execution‑linked validation of the platform by a leading oncology developer. Detailed mechanistic data: Not disclosed in the announcement.
Market Impact & Outlook
- Non‑Dilutive Capital: The USD 2 million milestone provides Adagene (NASDAQ: ADAG) with collaboration‑derived funding that validates platform economics without equity dilution; cumulative and potential future payments: Not disclosed.
- ADC Sector Momentum: Antibody‑drug conjugates remain one of oncology’s most active dealmaking arenas, and differentiated safety‑enhancement platforms such as SAFEbody are increasingly sought to solve the class’s toxicity ceiling.
- Dual‑Antigen Strategy: Targeting ROR1/2 positions XB404 within an emerging oncology antigen niche being pursued by several ADC and cell‑therapy developers, with tumor selectivity as the core differentiator.
- Pipeline Optionality: The agreement’s scope — covering monoclonal safe antibodies and SAFEbody ADC candidates — allows Exelixis to generate additional programs, each potentially triggering further milestones and royalties for Adagene.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the preclinical development of XB404, future milestone payments, royalty entitlements, and the broader SAFEbody collaboration with Exelixis. Actual results may differ materially due to risks including preclinical‑to‑clinical translation, safety and efficacy findings, regulatory requirements, partnership dynamics, and competitive developments in the ADC field.-Fineline Info & Tech